NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2025
0mins
Source: Newsfilter
NKGen Biotech's New Therapy: NKGen Biotech has initiated the administration of troculeucel, an autologous NK cell therapy, to a stroke patient under FDA's compassionate use IND, aiming to explore its potential in reducing chronic neuroinflammation and improving outcomes for stroke survivors.
Collaboration and Future Prospects: In partnership with George Washington University, NKGen is assessing the effects of troculeucel on brain injury markers, with hopes that this innovative therapy could lead to advancements in treating post-stroke conditions and other neurodegenerative diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
